Summit Insights Group analyst Kinngai Chan upgrades Micron Technology (NASDAQ:MU) from Hold to Buy.
CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks
CSL (OTC:CSLLY) announced topline Phase 3 results for garadacimab (CSL312) for hereditary angioedema (HAE). HAE is a rare genetic condition that…